AIMS: The aim of this study was to investigate the effects of liver X receptors (LXRs)-β preferential activation by LXR-623 (WAY-252623), a novel LXRs agonist, on plaque progression/regression in a rabbit model of advanced atherosclerosis. METHODS AND RESULTS: Advanced atherosclerosis was induced in New Zealand White Rabbits (n= 41). At the end of atherosclerosis induction, animals underwent a baseline magnetic resonance imaging (MRI) and were randomized to receive LXR-623 (1.5, 5, or 15 mg/kg/day), simvastatin (5 mg/kg/day), or placebo. The combination of LXR-1.5/simvastatin was also tested. After a final MRI, animals were euthanized and their aortas processed for further analysis. Simvastatin significantly reduced lesion progression (-25%; P< 0.01) in comparison with the placebo group. A similar effect was observed in the LXR-1.5 and -5 groups. A significant regression (16.5%; P< 0.01) of existing atherosclerosis was observed in the LXR-1.5/simvastatin group. Histological and molecular analysis showed plaque stabilization in the animals treated with the LXR-1.5 and -5, and LXR-1.5/simvastatin. The effects of LXR-623 were observed in the presence of a non-significant effect on total-cholesterol, low-density lipoproteins-cholesterol, and triglyceride levels. CONCLUSION: The results of the present study show that LXR-623 significantly reduces the progression of atherosclerosis and induces plaque regression in combination with simvastatin. These observations could drive future development of novel anti-atherosclerotic therapeutic approaches.
AIMS: The aim of this study was to investigate the effects of liver X receptors (LXRs)-β preferential activation by LXR-623 (WAY-252623), a novel LXRs agonist, on plaque progression/regression in a rabbit model of advanced atherosclerosis. METHODS AND RESULTS: Advanced atherosclerosis was induced in New Zealand White Rabbits (n= 41). At the end of atherosclerosis induction, animals underwent a baseline magnetic resonance imaging (MRI) and were randomized to receive LXR-623 (1.5, 5, or 15 mg/kg/day), simvastatin (5 mg/kg/day), or placebo. The combination of LXR-1.5/simvastatin was also tested. After a final MRI, animals were euthanized and their aortas processed for further analysis. Simvastatin significantly reduced lesion progression (-25%; P< 0.01) in comparison with the placebo group. A similar effect was observed in the LXR-1.5 and -5 groups. A significant regression (16.5%; P< 0.01) of existing atherosclerosis was observed in the LXR-1.5/simvastatin group. Histological and molecular analysis showed plaque stabilization in the animals treated with the LXR-1.5 and -5, and LXR-1.5/simvastatin. The effects of LXR-623 were observed in the presence of a non-significant effect on total-cholesterol, low-density lipoproteins-cholesterol, and triglyceride levels. CONCLUSION: The results of the present study show that LXR-623 significantly reduces the progression of atherosclerosis and induces plaque regression in combination with simvastatin. These observations could drive future development of novel anti-atherosclerotic therapeutic approaches.
Authors: Tamer Sallam; Ayaka Ito; Xin Rong; Jason Kim; Caroline van Stijn; Brian T Chamberlain; Michael E Jung; Lily C Chao; Marius Jones; Thomas Gilliland; XiaoHui Wu; Grace L Su; Rajendra K Tangirala; Peter Tontonoz; Cynthia Hong Journal: J Lipid Res Date: 2014-03-26 Impact factor: 5.922
Authors: Megan V Cannon; Herman H W Silljé; Jürgen W A Sijbesma; Inge Vreeswijk-Baudoin; Jolita Ciapaite; Bart van der Sluis; Jan van Deursen; Gustavo J J Silva; Leon J de Windt; Jan-Åke Gustafsson; Pim van der Harst; Wiek H van Gilst; Rudolf A de Boer Journal: EMBO Mol Med Date: 2015-09 Impact factor: 12.137
Authors: Ellen K Kick; Brett B Busch; Richard Martin; William C Stevens; Venkataiah Bollu; Yinong Xie; Brant C Boren; Michael C Nyman; Max H Nanao; Lam Nguyen; Artur Plonowski; Ira G Schulman; Grace Yan; Huiping Zhang; Xiaoping Hou; Meriah N Valente; Rangaraj Narayanan; Kamelia Behnia; A David Rodrigues; Barry Brock; James Smalley; Glenn H Cantor; John Lupisella; Paul Sleph; Denise Grimm; Jacek Ostrowski; Ruth R Wexler; Todd Kirchgessner; Raju Mohan Journal: ACS Med Chem Lett Date: 2016-10-23 Impact factor: 4.345
Authors: Luwanika Mlera; Danielle K Offerdahl; David W Dorward; Aaron Carmody; Abhilash I Chiramel; Sonja M Best; Marshall E Bloom Journal: Emerg Microbes Infect Date: 2021-12 Impact factor: 7.163